Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the tests stopped selling. Revenue fell, the stock retreated, and investors spent the better part of two years deciding what Abbott actually was without the pandemic tailwind. That question is now sharper than ever, because on October 21, 2026, Abbott answered it in a way nobody quite expected: by announcing it would cut itself in two.
The math and the mood, as we use those terms here, are pulling in opposite directions. “The math” is what the filed numbers justify on their own terms. “The mood” is what the market is currently willing to pay. Right now, Abbott’s math says accelerating revenue; the mood says the stock should fall. Both happened on the same day, and the gap between them is the story.
What the numbers say
Abbott’s Q3 2026 filing shows net sales of $13 billion, up nearly 15% from the same quarter a year ago, with every business segment growing. Yet operating income fell, net income fell, and the stock dropped on the day of the announcement. The company is simultaneously growing faster and earning less per dollar of sales than it was twelve months ago, a combination that demands explanation. The planned spin-off of the nutrition business, announced the same day, is management’s answer, but the market is still working out whether it is a solution or an admission.
How Abbott Got Here
For most of its history, Abbott was the kind of company pension funds loved: diversified, predictable, growing about as fast as the economy. COVID-19 changed that. Rapid antigen tests flooded the books, pushing FY2024 revenue to $42 billion and, because those tests carried fat margins, net margin briefly touched levels the company had rarely seen. Then the tests faded. By the FY2025 annual report, filed February 20, 2026, revenue had recovered to $44.3 billion but net margin had compressed back to roughly 15%, closer to Abbott’s pre-pandemic norm.
The March 2026 acquisition of Exact Sciences for $21 billion, adding cancer-screening technology to the diagnostics portfolio, was the most consequential strategic move in years. A deal that size costs more than Abbott earns in a typical year, so it reshapes the balance sheet as much as the income statement. The company ended 2025 with $8.5 billion in cash against $12.9 billion in total debt, a net debt position that is manageable but not trivial.
Then came the infant formula litigation. Abbott agreed in September 2026 to pay roughly $385 million to resolve allegations tied to its 2022 formula recall, a reminder that the nutrition business carries legal tail risk that the devices and diagnostics segments do not. That context matters for understanding why management chose this moment to separate the two.
The Quarter That Confused Everyone
The Q3 2026 numbers contain a genuine puzzle. Sales grew 14.5% year over year, which is fast for a company of this size. Every segment posted growth: diagnostics, medical devices, established pharmaceuticals, and nutrition all expanded. Cancer diagnostics, the piece of the business that Exact Sciences brought in, grew at double-digit rates in the quarter. A blood-based colorectal cancer screening test received FDA approval in September 2026, adding a new commercial product to that pipeline.
And yet operating income fell and net income dropped alongside it. The reason is that absorbing a $21 billion acquisition creates costs, amortization charges, and integration expenses that suppress reported earnings even as underlying sales accelerate. The adjusted gross margin, which strips those acquisition-related items out, actually expanded to 57.2% of sales, up about 140 basis points year over year, according to the Q3 2026 earnings call highlights. Think of it as the difference between what a business earns before the accountants finish tallying the acquisition paperwork and what it earns after.
The mood soured anyway, because management trimmed the full-year 2026 comparable sales growth outlook, cutting the top and bottom of the range it had previously set. A guidance cut, even a modest one, tells investors that management’s own confidence has softened, and markets tend to reprice that signal quickly.
The Spin-Off Bet
CEO Robert Ford described the planned nutrition spin-off, expected by end of 2027, as positioning the remaining Abbott for “stronger growth and margins.” The logic is straightforward: nutrition is a substantial annual business growing at mid-single digits, while devices and diagnostics are growing faster and carry higher margins. Bundling them together dilutes the growth rate and the margin profile of the faster businesses. Separating them lets each be valued on its own terms.
Management projects that removing nutrition would lift the remaining company’s comparable sales growth by 50 to 100 basis points and expand gross margins by more than 200 basis points. Those are meaningful improvements for a business at this scale. The full-year adjusted EPS guidance, and the specific range provided for Q4, reflect the current combined company, not the post-spin structure. Those figures are detailed in the Q4 2026 earnings call transcript.
Investors watching continuous glucose monitors, Abbott’s Libre franchise, noted some deceleration in that segment. That is worth watching, because glucose monitoring has been one of the fastest-growing pieces of the medical devices business. A slowdown there would matter more to the post-spin Abbott than it does to the current conglomerate.
What the Price Is Assuming
At roughly $100, Abbott trades at a price-to-earnings multiple that sits almost exactly at its own decade median, which sounds like fair value. But the price-to-sales ratio, which compares the stock’s total price tag to annual revenue, sits well below that same decade median, at the 16th percentile of Abbott’s own history. A family that typically paid nearly five dollars for every dollar of a business’s annual sales is now being offered the same business for considerably less. That gap can mean the business has genuinely deteriorated, or it can mean the price has fallen faster than the fundamentals.
TD Cowen analyst Joshua Jennings reaffirmed a positive outlook and cited a valuation reference of $135 on October 16, 2026. Barclays initiated coverage with an Overweight rating and a valuation reference of $120 on October 7, 2026. The average valuation reference across roughly twenty analysts sits near $119. We cannot verify the internal models behind those figures, and BullScope does not endorse them. What we can say is that the stock is trading meaningfully below that consensus figure, which means the mood is considerably darker than the math those analysts are running.
If the post-spin Abbott delivers the margin expansion management projects, and if the Exact Sciences integration produces the cancer-diagnostics growth already visible in Q3, the filed-trend math would support a materially different valuation than today’s price implies. But the spin does not close until end of 2027 at the earliest, the glucose monitor slowdown is unresolved, and the litigation tail from nutrition has not fully cleared. Those are real uncertainties, and honest accounting of them is the price of credibility.
Reading the Numbers
- $13 billion in Q3 2026 net sales, up 14.5%. This is what Abbott billed customers in a single quarter. The 14.5% growth rate is fast for a company this size, roughly three times the pace of the broader economy. It matters because it shows the Exact Sciences deal is adding revenue, not just cost. Filed in the Q3 2026 earnings release. A household analogy: if a family’s income grew 14.5% in a year, they would have gone from earning $70,000 to nearly $80,000.
- Operating income fell to $1.36 billion from $1.46 billion. Operating income is what’s left of each dollar of sales after paying the bills to run the business, before interest and taxes. The drop, despite higher sales, reflects acquisition-related charges from the Exact Sciences deal. It means Abbott is temporarily paying more to digest a large purchase than it is gaining in operating profit. Once integration costs wind down, the trend should reverse, but the data cannot yet confirm when.
- Adjusted gross margin of 57.2%, up 140 basis points. A basis point is one-hundredth of a percentage point, a unit analysts use to describe small but meaningful changes. Gross margin is what remains of each dollar of sales after the direct cost of making the product. At 57 cents on every dollar, Abbott keeps more than half of each sale before paying for offices, salespeople, or research. The improvement means the underlying product mix is getting more profitable even as the headline earnings number falls.
- $7.4 billion in free cash flow for FY2025. Free cash flow is the actual cash a business generates after spending what it needs to maintain and grow its operations, the number closest to what a business truly earns. At $7.4 billion, Abbott generated more cash in 2025 than most companies earn in total revenue. Filed in the FY2025 10-K. That cash funded the dividend, which currently yields about 2.4%, roughly 50% more than the healthcare sector average.
- P/S ratio at the 16th percentile of Abbott’s own decade. This means that in roughly 84% of the months over the past ten years, investors paid more per dollar of Abbott’s sales than they do today. It does not guarantee the price rises, but it does say the current mood is historically cautious relative to this business’s own track record.
Reading the numbers
14.5% revenue growth on $13 billion in quarterly sales. Net sales is the total amount Abbott billed customers in the quarter, after returns and discounts. Growing that number by 14.5% in a single year is unusually fast for a company this large, most mature healthcare companies grow at roughly the pace of the economy, around 3% to 5%. The figure matters here because it shows the Exact Sciences acquisition is adding real customers and real billings, not just accounting entries. It is the clearest evidence that the deal is working on the top line, even before the cost savings arrive.
Operating income fell from $1.46 billion to $1.36 billion. Operating income is what remains of each dollar of sales after paying every cost of running the business, manufacturing, salaries, research, and administration, but before interest on debt or taxes. The fact that this number shrank while revenue surged is the central puzzle of the quarter. The explanation is acquisition accounting: when a company pays $21 billion for another business, it must spread a portion of that purchase price across future years as an amortization charge, a non-cash cost that reduces reported profit even though no cash leaves the door in that period. The drop does not mean Abbott’s operations deteriorated; it means the accountants are still tallying the price of the Exact Sciences deal. It moves the story because it is the number that caused the stock to fall on a day of strong sales growth.
Adjusted gross margin of 57.2%, up 140 basis points year over year. Gross margin measures what Abbott keeps from each dollar of sales after paying only the direct cost of making its products, materials, manufacturing labour, and the like. At 57 cents on the dollar, Abbott retains more than half of every sale before a single office light is switched on. The 140-basis-point improvement (1.4 percentage points) matters because it is the number that strips away the acquisition noise and shows the underlying business getting more profitable, not less. It is the counter-argument to the falling operating income: the core products are healthier; the drag is temporary paperwork from a large deal.
For the standing yardsticks on Abbott Laboratories: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Abbott Laboratories.
Sources
- Abbott Q3 2026 earnings release (SEC EDGAR)
- Abbott 10-K FY2025 (SEC EDGAR)
- Abbott 10-K FY2024 (SEC EDGAR)
- GuruFocus: Abbott Q3 2026 earnings call highlights
- Biggo Finance: Abbott Q3 2026 earnings call
- Investing.com: Abbott Q3 2026 earnings call transcript
- MarketBeat: Abbott analyst forecasts
- Benzinga: Abbott analyst valuation reference changes, October 2026
- Financial Content: Abbott completes Exact Sciences acquisition
